Biophytis S.A. - Asset Resilience Ratio
Biophytis S.A. (BPTSY) has an Asset Resilience Ratio of 1.30% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how Biophytis S.A.'s Asset Resilience Ratio has changed over time. Check BPTSY capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Biophytis S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Biophytis S.A. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $113.00K | 1.3% |
| Total Liquid Assets | $113.00K | 1.30% |
Asset Resilience Insights
- Limited Liquidity: Biophytis S.A. maintains only 1.30% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biophytis S.A. Industry Peers by Asset Resilience Ratio
Compare Biophytis S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Biophytis S.A. (2012–2023)
The table below shows the annual Asset Resilience Ratio data for Biophytis S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 3.08% | $368.00K | $11.96 Million | +0.39pp |
| 2022-12-31 | 2.68% | $590.00K | $21.99 Million | -0.71pp |
| 2021-12-31 | 3.39% | $1.23 Million | $36.26 Million | -44.11pp |
| 2020-12-31 | 47.50% | $12.92 Million | $27.21 Million | +44.81pp |
| 2019-12-31 | 2.69% | $475.00K | $17.67 Million | -20.18pp |
| 2018-12-31 | 22.87% | $5.00 Million | $21.86 Million | -15.67pp |
| 2017-12-31 | 38.54% | $10.00 Million | $25.95 Million | +38.54pp |
| 2015-12-31 | 0.00% | $367.00 | $13.52 Million | -24.83pp |
| 2012-12-31 | 24.84% | $300.49K | $1.21 Million | -- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, … Read more